证券代码：300430 证券简称：诚益通 公告编号：2026-002 北京诚益通控制技术集团股份有限公司 关于为上市公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 二、融资进展情况 近期，北京诚益通科技有限公司（以下简称"诚益通科技"）与江苏银行股 份有限公司北京分行（以下简称"江苏银行"）签署《最高额保证合 ...

1月16日，诚益通跌5.28%，截至发稿，报24.24元/股，成交1.74亿元，换手率2.69%，总市值66.19亿 元。 资料显示，北京诚益通控制技术集团股份有限公司位于北京市大兴区生物医药产业基地庆丰西路27号， 成立日期2003年7月22日，上市日期2015年3月19日，公司主营业务涉及提供医药、生物工业自动化控制 系统整体解决方案;康复理疗医疗器械的研发、生产和销售业务。主营业务收入构成为：控制系统 54.65%，康复医疗器械28.89%，系统设备及其他16.47%。 从诚益通十大流通股东角度 数据显示，长城基金旗下1只基金位居诚益通十大流通股东。长城消费增值混合A（200006）三季度新 进十大流通股东，持有股数200万股，占流通股的比例为0.77%。根据测算，今日浮亏损失约270万元。 长城消费增值混合A（200006）成立日期2006年4月6日，最新规模5.16亿。今年以来收益21.73%，同类 排名56/8847；近一年收益44.1%，同类排名2734/8094；成立以来收益315.35%。 长城消费增值混合A（200006）基金经理为龙宇飞。 截至发稿，龙宇飞累计任职时间8年93天，现任基金 ...

Group 1 - Guangzhou Longzhijie Health Industry Co., Ltd. has been established, with Tian Zhuang as the legal representative [1] - The company's business scope includes the sale of Class I and Class II medical devices, sales of mechanical and electrical equipment, medical equipment leasing, and installation services for general machinery [1] - The company is wholly owned by Chengyitong through indirect shareholding [1]

Core Viewpoint - Chengyitong's rehabilitation segment, Longzhijie, offers a comprehensive elderly rehabilitation solution suitable for community elderly service centers and home care scenarios, including equipment supply, technical support, and training services [2] Group 1: Product Offerings - Longzhijie provides a variety of products for rehabilitation, including exercise rehabilitation devices for elderly limb function recovery, such as active and passive rehabilitation instruments, limb coordination systems, and balance assessment and training systems [2] - The product range also includes physical therapy items like various electrical stimulation products, pneumatic limb products, and magnetic stimulation products [2] - Additionally, auxiliary products are offered, such as training beds and overhead transfer systems [2] Group 2: R&D and Market Understanding - Longzhijie possesses strong research and development capabilities, having established a mature system for R&D, production, sales, and service [2] - The company has a deep understanding of the rehabilitation needs of the elderly population due to years of industry experience [2]

Industry Overview - Brain-Computer Interface (BCI) is a new cross-disciplinary technology that creates a communication channel between the brain and external devices, enabling direct information exchange [6] - BCIs can be classified into three types: invasive, semi-invasive, and non-invasive, with applications in medical rehabilitation, consumer interactions, and military fields [7] - The global BCI market is projected to reach $7.63 billion by 2029, growing from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% from 2019 to 2023 [13][14] - Over 1,500 financing events in the global BCI sector have raised nearly $10 billion, with significant investments in both the U.S. and China [16] Policy Guidance - Major countries have launched brain initiatives to support BCI development, with the U.S. investing approximately $4.5 billion in its BRAIN Initiative since 2013 [37][40] - China has initiated its "Brain Science and Brain-Like Intelligence Technology" project, with funding expected to reach hundreds of billions of yuan [39][42] Clinical Situation - The medical demand for BCIs is driven by the need for rehabilitation in stroke and disabled populations, with significant clinical research already underway for various diseases [3][33] - Clinical trials for BCIs are accelerating globally, with a rapid increase in the number of trials in China [3][11] Industry Progress - Notable advancements include Neuralink's implantation of over 10 devices and Synchron's achievement of brain-controlled iPad functionality [4][4] - Key overseas companies like Neuralink and Synchron are leading in the invasive BCI field, focusing on treatment and human-computer interaction [4][4] - Domestic companies are also making strides, with clinical trials accelerating and real-time Chinese language decoding being achieved [4][4] Industry Chain Analysis - The BCI industry chain consists of upstream hardware and software supply, midstream BCI product supply, and downstream applications in various fields [18] - Upstream technology innovation barriers are high, with breakthroughs in flexible electrodes and chips being critical [20][21] - Downstream applications are primarily in the medical field, which is the most mature area for commercialization [30]

Group 1 - The core viewpoint of the article highlights a significant surge in A-share market stocks related to brain-computer interface (BCI) technology, driven by recent developments in the sector [1] - Aipeng Medical reached a 20% daily limit increase, while Kefu Medical rose over 15%, indicating strong investor interest in BCI-related companies [1] - Notable stocks such as Nanjing Panda, Pulite, and Innovation Medical achieved a 10% daily limit increase, reflecting a broader trend of positive market sentiment towards BCI stocks [1] Group 2 - The article mentions that on January 6, Strong Brain Technology, a leading company in the BCI field, announced the completion of approximately 2 billion RMB in financing, marking a significant milestone for the industry [1] - This financing round is noted to be the second largest globally in the BCI sector, only behind Neuralink, which is owned by Elon Musk [1] - The financing success of Strong Brain Technology is expected to further stimulate interest and investment in the BCI market, potentially leading to more advancements and innovations in the field [1]

Market Overview - The three major A-share indices experienced slight increases, with the Shanghai Composite Index rising by 0.05% to 4085 points, the Shenzhen Component Index increasing by 0.06%, and the ChiNext Index up by 0.31% [1][2] - The total market turnover reached 2.88 trillion yuan, an increase of 49.3 billion yuan compared to the previous trading day, with nearly 3200 stocks declining [1] Index Performance - Shanghai Composite Index: 4085.77 (+2.11, +0.05%) [2] - Shenzhen Component Index: 14030.56 (+8.01, +0.06%) [2] - ChiNext Index: 3329.69 (+10.40, +0.31%) [2] - Sci-Tech 50 Index: 1443.39 (+14.09, +0.99%) [2] - CSI 300 Index: 4776.67 (-14.03, -0.29%) [2] - CSI 500 Index: 7875.08 (+60.95, +0.78%) [2] Sector Performance - The storage chip sector saw a significant surge, with companies like Tongcheng New Materials and Hengkun New Materials hitting the daily limit [1][3] - The electronic chemicals sector also rose, with Guanggang Gas hitting the daily limit [1][3] - The photolithography machine sector strengthened, with companies like Nanda Optoelectronics reaching the daily limit [1][3] - The media sector experienced gains, with companies such as Dayou Energy and Shanxi Black Cat hitting the daily limit [3] Declining Sectors - The DRG/DIP concept saw a decline, with Rongke Technology hitting a 20% limit down [3] - The brain-computer interface sector faced a significant pullback, with companies like Chengyitong and Aipeng Medical dropping over 10% [3] - The titanium dioxide sector weakened, with Zhenhua Co. leading the decline [3] - Sectors related to digital currency, under-screen photography, and brokerage concepts also experienced notable declines [3]

| 代码 | 名称 | | 涨幅% ↑ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688273 | 麦澜德 | 1 | -11.09 | 54.43 乙 | 28.01 | | 300430 | 诚益通 | 1 | -10.91 | 67.31亿 | 28.25 | | 301330 | 熵基科技 | 1 | -10.40 | 100亿 | 29.02 | | 300753 | 爰朋医疗 | 1 | -10.39 | 45.14亿 | 29.05 | | 300652 | 雷迪克 | 中 | -8.34 | 82.53 Z | 12.78 | | 688580 | 伟思医疗 | 1 | -8.03 | 61.39亿 | 32.44 | | 603579 | 荣泰健康 | 1 | -6.80 | 54.60亿 | 12.77 | | 301087 | 可孚医疗 | 1 | -6.44 | 99.25亿 | 6.36 | | 300884 | 狄耐克 | 1 | -6.19 | 42.34亿 | 12.70 | | 603610 | 麒盛科 ...

脑机接口板块午后跳水，诚益通、爱朋医疗、熵基科技跌超10%，翔宇医疗、麦澜德、伟思医疗纷纷下 挫。 ...

消息面上，多家脑机接口概念股出降温公告。其中，航天长峰称公司未实际开展脑机接口等相关业务； 伟思医疗称在脑机接口领域的新产品仍处于市场培育初期。 格隆汇1月7日｜A股市场部分脑机接口概念股明显回调，其中，麦澜德、熵基科技跌超10%，诚益通、 雷迪克跌超7%，博拓生物、爱朋医疗跌超6%，可孚医疗、翔宇医疗跌超5%，狄耐克、伟思医疗跌超 4%。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 ...